Athletes, fitness enthusiasts, and bodybuilders who are using GLP-1 medications while trying to maintain training performance and muscle mass fall into this category
Log in below to join the conversation.
Similar benefits were seen in the lupus nephritis subgroup
In contrast to other AOMs, which either suppress appetite or inhibit fat absorption [23], GLP-1RAs reduce body weight in a number of ways, decreasing appetite and hunger, and increasing satiety, resulting in reduced energy intake [24,25,26]
This includes predictable meals and snacks, flexibility at school or work to accommodate appointments and meal timing, and compassionate communication that reduces shame and blame
Specifically, the program entails "a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027. More details are forthcoming on the program, especially as part of a larger and wider scoped initative for the decade ahead: The future of Medicare coverage hinges on something called the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) model, which will attempt to integrate GLP-1s into the standard benefit package more permanently. Indeed, this remains one of the most important conversations taking place in medicine currently